ClinicalTrials.gg
RecruitingNCT07863466Updated Oct 7, 2026

MPNdpoint. Single-center, Retrospective, Prospective Study of the Outcome of Patients With Philadelphia-negative Chronic Myeloproliferative Neoplasms

An observational study in Myelofibrosis (MF), Polycythemia Vera and Essential Thrombocythaemia, sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico. Recruiting at 1 site in Italy. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Observational

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.
Updated Oct 7, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
1,190
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 101 studies in Primary Myelofibrosis with a site in Italy — 24 open to participants now, 43 under way, 11 of them phase 3. Primary Myelofibrosis · Italy.

Planned enrollment
2nd of 18
1,190 · median 448
Started
2025
with 3 others
Observational
18 of 101
5 open now
Primary completion
2044-06
later than 42 of 42 live
Registered
101st of 101
by date

Among the 101 studies in Primary Myelofibrosis with a site in Italy, this one is the 2nd largest by planned enrollment of the 18 observational ones that give a count, is one of 4 that started in 2025, is one of 18 observational ones, reaches primary completion later than 42 of the 42 other live ones, and was the 101st registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

24 of the 101 studies in Primary Myelofibrosis with a site in Italy are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 11 take children under 18; 7 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies in Primary Myelofibrosis with a site in Italy, or all of them as a file.
02

Study summary

Chronic myeloproliferative neoplasms (MPNs) are hematologic disorders of the myeloid lineage characterized by clonal proliferation of hematopoietic stem cells, high risk of thrombotic-hemorrhagic complications, and transformation into secondary acute myeloid leukemia. MPNs include: myelofibrosis, polycythemia vera, and essential thrombocythemia. The low incidence, comparable to that of rare diseases, induces the in-depth study of patients and thus the need to develop a project with databases to collect clinical, biological, and therapeutic information.

03

Conditions studied

  • Myelofibrosis (MF)
  • Polycythemia Vera
  • Essential Thrombocythaemia

Keywords

  • Myelofibrosis
  • Polycythemia Vera
  • Essential Thrombocythemia
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients 16 years of age and older, diagnosed with polycythemia vera, essential thrombocythemia, prefibrotic and overt primary myelofibrosis, secondary myelofibrosis, followed at Policlinico Hospital (MIlan, Italy)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients 16 years of age and older
  • Patients diagnosed with polycythemia vera, essential thrombocythemia, prefibrotic and overt primary myelofibrosis, secondary myelofibrosis (Arber et al, Blood 2022 or earlier but reclassified classifications)

Exclusion criteria

Exclusion Criteria:

  • Patients with diagnosis other than polycythemia vera, essential thrombocythemia, prefibrotic and overt primary myelofibrosis, secondary myelofibrosis
  • Follow up of less than 6 months
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
1,190 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Overall Survival

    Time frame: 20 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Jun 2044, 232 months after the start.

Of 23 observational studies under Primary Myelofibrosis, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 119. This study's planned 232 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2026
First posted
Oct 7, 2026
StartActual
Feb 17, 2025
Primary completionEst.
Jun 2044
CompletionEst.
Jun 2044
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07863466
Responsible party
Sponsor
First posted
Oct 7, 2026
Start date
Feb 17, 2025
Primary completion
Jun 2044 (estimated)
Completion
Jun 2044 (estimated)
Last update
Oct 7, 2026

Study contacts

Barbara Mora, MD
Contact
barbara.mora@policlinico.mi.it
+39 0255033345

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion